BIOPHARMA
By
Did AbbVie Successfully Manage 2025 Headwinds, and Are Rinvoq and Skyrizi Poised to Reach $31B+ Sales by 2027?
NORTH CHICAGO, ILLINOIS — As 2025 comes to a close, AbbVie reflects on a year marked by strong…
Is Lilly Shaping Its Post-Blockbuster Future Through Verve, Superluminal, and AI-Driven Partnerships in 2025?
In 2025, Eli Lilly and Company approached dealmaking from a position of strength. With blockbuster brands driving growth…
Is Lilly Strengthening Its 2026 Growth Outlook by Scaling Zepbound, Mounjaro, and Its Core Innovation Engine in 2025?
In 2025, Eli Lilly and Company continued to build on its strong momentum, executing a focused strategy centered…
Pfizer’s Strategic Deals in 2025: Key Moves Shaping the Company’s Next Phase
Strategic Takeaways In 2025, Pfizer executed a series of focused and strategic deals aimed at strengthening its pipeline,…
Can AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth Beyond 2026?
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Can Merck’s 2025 Launches, Label Expansions, and Oncology Leadership Sustain Growth Momentum Into 2026 and Beyond?
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada) reinforced its position…
